🇦🇹 Representative genomic surveillance of SARS-CoV-2 in Austria in week 42 across all regions. Nowcasting in dashed box shows the current situation. A collaboration of #AGES@agesnews and @IMBA_Vienna/@oeaw. 1/6
BA.5 with R346T has reached ~25% now. New variants such as BQ.1(.1) and XBB show clear growth. BQ.1(.1) currently at ~8%, XBB<1%. 2/6
Due to the good weather (see journals.plos.org/ploscompbiol/a…) and declining case counts of BA.5 we currently observe a strong reduction in absolute numbers. 3/6
The “vicious dozen” of mutations with currently particularly high selection pressure within the spike protein relative to BA.2 are listed below. Some are already present in BA.5, others are coming up now. 4/6
For simplicity and to maintain oversight in the variant swarm, experts like @CorneliusRoemer and many others suggested binning variants into levels based on how many of those mutations they already picked up relative to BA.2. Austrian results:
So the calm before the storm will in all likelihood end in November with a change of weather and the new variants taking over. Rather abruptly...
6/6
• • •
Missing some Tweet in this thread? You can try to
force a refresh
🧵To mask or not to mask, this is the question again.
With winter starting in the northern hemisphere, masks are discussed many places. Some thoughts within the range of realistic options:
A.For societies
B.For individuals
A. Any form of enforced mask mandate as seen in some countries previously of course is a stress test for societies and generally disfavoured by most, but also requested by many. Some arguments for society level reactions:
A.1 One might argue that dampening one wave with masks just means the next wave is higher. Connected vessels. Only true however if we assume that one wave generates immunity against the next, this was neither true always in the past nor is it projected to be the case this winter.
Currently there is a trend towards convergent evolution in SARS-CoV-2. But is that the whole picture? All roads to Rome and that’s it? Or where do we go from here?
My 2 cents in an illustrated 😊 thread…. 1/
We have built a polyclonal B-cell immunity to counteract a SARS-CoV-2 infection, that we all cherish. But as we get closer to the edge of it, mutations in the spike protein gain more advantage to escape that defense. 2/
With the initial variant this was less likely to occur, but with BA.1 and even more so BA.2 there is more immune erosion and drops get more frequent. Modified from this wonderful study. biorxiv.org/content/10.110… 3/
Looking like with the latest turn of direction the virus has managed to escape our immune system efficiently yet again.
There is an unprecedented number of highly diverged variants coming up and two brand-new studies shed light on this concerning situation.
Amazing work! 1/
In one study, Ben Murrell and colleagues show five-fold escape from serum neutralization by BA.2.75.2 in pseudovirus assay. biorxiv.org/content/10.110…
2/
In another very impressive study, Xiaoliang Sunney Xie and colleagues study many current sub-sub variants comprehensively. 3/ biorxiv.org/content/10.110…
Mutational differences between important SARS-CoV-2 lineages within the antibody binding regions of the spike protein. Shown is NTD (defined here as amino acid 1-300) and RBD (301-600) separate and together. 1/4
This rainbow-painted spike (blue to red) shows the N-terminal domain in shades of blue followed by RBD in shades of green for comparison. 2/4
Mutation space differences must not be confused with immunological distance, but do hint towards vaccine efficiency. The upcoming lineages BA.2.75.2 and BJ.1 are 33/36 mutations away from WT, 31/28 from BA.1, and 13/17 from BA.5. 3/4
Another sublineage of great concern is expanding in India and has also made landfall in the US and Europe (Austria): BJ.1
Numbers are still very low, but the newly acquired mutations are really a nasty combination in critical places. 1/7
The lineage was noticed already a month ago, you can follow the details and expansion in this pango-designation issue: github.com/cov-lineages/p…
Thanks to all the colleagues keeping such good track of the variant-zoo!
2/7
BJ.1 is a BA.2 sublineage with 14 additional mutations in spike (plus others). What is immediately obvious is, that the many new mutations cluster densly in the receptor binding domain and the NTD antibody binding “supersite”. 3/7